title: Treatment of transient neonatal diabetes mellitus: insulin pump or insulin glargine? Our experience.
abstract: Neonatal diabetes mellitus (NDM) results from impaired insulin secretion, occurring within the first 6 months of life. NDM is classified as transient NDM (TNDM) or permanent NDM. To date there are no universal guidelines regarding its management. Intravenous insulin infusion represents the first and most adequate therapeutic approach for sustained hyperglycemia, but this can provide only a short-term solution. Several factors should be taken into account in the choice of the long-term treatment. We describe our experience with two infants affected by TNDM. The first child was treated with continuous subcutaneous insulin infusion, whereas the second infant was treated with subcutaneous insulin glargine injections. Our experience shows that the two different therapeutic approaches, if properly managed, are equally effective.
authors.affiliation: 1 Department of Medical and Pediatric Sciences, University of Catania , University Hospital Vittorio Emanuele, Catania, Italy .
authors.forename: Stefano
authors.initials: S
authors.lastname: Passanisi
authors.forename: Tiziana
authors.initials: T
authors.lastname: Timpanaro
authors.forename: Donatella
authors.initials: D
authors.lastname: Lo Presti
authors.forename: Corrado
authors.initials: C
authors.lastname: Mammì
authors.forename: Manuela
authors.initials: M
authors.lastname: Caruso-Nicoletti
mesh_terms: D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control*; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069036:Insulin Glargine; D007332:Insulin Infusion Systems; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007558:Italy; D057285:Precision Medicine; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine